IHS Chemical Week

Regions :: Western Europe :: U.K.

Merck & Co. to Acquire Biologics Activities of Avecia

10:37 AM MST | December 22, 2009 | Alex Scott

Pharmaceuticals giant Merck & Co. says it has agreed to purchase the contract biologic drugs manufacturing activities of Avecia (Tees Valley, U.K.). Financial details were not disclosed. Avecia Biologics is a contract manufacturing organization with specific expertise in microbial-derived biologics. The oligomedicines Business of the Avecia group based in the U.S. does not form part of this transaction.   Under the terms of the agreement, Merck will acquire Avecia Biologics Limited and all its assets, including all the company's process development and...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa